Introduction
============

Mycotic thoracic abdominal aortic aneurysms are rare, accounting for fewer than 1% of all aortic aneurysms. They are associated with a high incidence of fatal rupture when medical therapy alone is attempted. Although there are no standard guidelines for treatment, the most common practice is to combine antibiotic therapy with surgical resection and graft interposition \[[@b1-kjtcv-50-430]--[@b3-kjtcv-50-430]\]. The purpose of this study was to assess the midterm outcomes of open repair of mycotic aortic aneurysms with soft-tissue coverage during a 10-year period at the Severance Hospital, Yonsei University College of Medicine.

Methods
=======

From January 2006 to December 2016, 19 patients underwent open repair of a mycotic aortic aneurysm. We reviewed prospectively collected data to identify patients who underwent surgical repair for mycotic aortic aneurysms. This study was conducted following approval by the Institutional Review Board of the Yonsei University College of Medicine (IRB number: 4_2011_0173). The individual patient consent was waived. Aneurysms were defined as mycotic if its characteristic appearance was observed in radiologic imaging or during an intraoperative examination, and if positive cultures were obtained from either blood or aortic tissue. Computed tomography (CT) imaging was used to determine whether the aneurysm was rapidly growing, had newly developed, and whether there was air in the aortic wall or a soft-tissue mass surrounding the aneurysmal aorta. The primary endpoints were in-hospital mortality and late death from any cause. The secondary endpoints were early major complications and a composite of late aortic events.

1) Surgical technique
---------------------

All procedures were performed with sternotomy, left thoracotomy, or left thoracoabdominal or median abdominal incision, depending on the anatomic location of the aneurysm. Infected tissues were completely excised, and aortic continuity was restored with a Dacron prosthesis (Macquet Corp., Oakland, NJ, USA), homograft, or Gore-Tex (W. L. Gore & Associates, Elkton, MD, USA) graft. Cryopreserved arterial homografts were used in infections that were not controlled by antibiotic therapy. Soft-tissue coverage of the prosthesis was performed when permitted by the anatomy and patient condition \[[@b1-kjtcv-50-430],[@b4-kjtcv-50-430],[@b5-kjtcv-50-430]\].

2) Statistics
-------------

Data processing and analysis were performed using IBM SPSS ver. 20.0 (IBM Corp., Armonk, NY, USA). Results are expressed as frequency and percentage for categorical variables and as mean and standard deviation for continuous variables. All p-values \<0.05 were considered to indicate statistical significance. Survival estimates were generated using the Kaplan-Meier method.

Results
=======

1) Patients and characteristics
-------------------------------

Patient characteristics are listed in [Table 1](#t1-kjtcv-50-430){ref-type="table"}. The median age was 62±7.2 years (range, 16 to 78 years). The series of 19 patients consisted of 13 men (68.4%) and 6 women (31.6%). Nine patients (47.4%) had at least 1 comorbid condition associated with some degree of immunosuppression, including 6 (31.6%) with diabetes mellitus, 4 (21.0%) with chronic renal disease, or 2 (10.5%) with benign or malignant tumors.

2) Symptoms and clinical findings
---------------------------------

In this study, 95% of patients presented with aneurysm-related symptoms: pain (n=10, 53%), fever (n=8, 42%), or hematochezia or hemoptysis (n=4, 21%). Preoperative CT was performed in all patients; the mean aneurysm size was 44.5±4.9 mm. Six patients (31.5%) had a contained rupture at the time of surgery. The average duration of symptoms before surgery was 14.5±4.7 days.

3) Anatomic location
--------------------

Of the 19 mycotic aneurysms, 3 (15.8%) were ascending, 6 (31.6%) were descending thoracic, 2 (10.5%) were thoracoabdominal, and 8 (42.1%) were abdominal.

4) Surgical procedure
---------------------

Following radical debridement of the infected tissue, Dacron grafts (n=15, 78.9%) ([Fig. 1A](#f1-kjtcv-50-430){ref-type="fig"}), cryopreserved arterial homografts (n=3, 15.8%) ([Fig. 1B](#f1-kjtcv-50-430){ref-type="fig"}), or a Gore-Tex graft (n=1, 5.3%) was placed *in situ* in the normal anatomic position. Nine patients (47.4%) had additional soft-tissue coverage, including 8 (42.1%) with an omental flap ([Fig. 1C](#f1-kjtcv-50-430){ref-type="fig"}) and 1 (5.3%) with a pectoralis major muscle flap ([Table 2](#t2-kjtcv-50-430){ref-type="table"}).

5) Bacteriology and antibiotic treatment
----------------------------------------

Blood cultures were positive for *Staphylococcus aureus* in 4 patients (21%), while 3 (15.7%) had *Enterobacter* species. Nine (47%) had negative culture results. The remaining results of the bacteriological analysis are outlined in [Table 2](#t2-kjtcv-50-430){ref-type="table"}. Patients were initially administered broad-spectrum antibiotics, followed by targeted antibiotics after the causative organisms were identified and their susceptibility analyzed. Broad-spectrum intravenous antibiotics were administered in the early postoperative period for 4--6 weeks and then replaced by oral therapy based on the results of the bacteriological analysis \[[@b6-kjtcv-50-430],[@b7-kjtcv-50-430]\].

6) Short-term outcomes
----------------------

The mean intensive care unit (ICU) stay and in-hospital stay were 11±19.7 and 52±44.6 days, respectively. There were 2 in-hospital deaths (10.5%), secondary to sepsis and acute myocardial infarction.

7) Long-term outcomes
---------------------

The mean follow-up time of the patients was 43.2±11.7 months. Two patients (10.5%) died of aneurysm-related complications during the follow-up period. One patient presented 32.4 months postoperatively with massive hematemesis due to an aorto-enteric fistula. Another patient died 61.9 months postoperatively due to sepsis from a mediastinal abscess resulting from graft reinfection ([Table 1](#t1-kjtcv-50-430){ref-type="table"}). During follow-up, 1 patient had a prosthetic graft reinfection, as mentioned above. None of the patients had a spinal cord injury or stroke. One patient required new-onset dialysis and developed permanent renal failure. None of the patients underwent reoperation. The 5-year survival rate after surgery was 74.9%±11.5% ([Fig. 2](#f2-kjtcv-50-430){ref-type="fig"}).

Discussion
==========

Mycotic aneurysms were first described by Osler in 1885, referring to infected aneurysms secondary to septic embolisms due to endocarditis. The incidence of infected aneurysms is higher when invasive monitoring techniques, angiography, and other percutaneous techniques are performed; it is also higher in patients with immunosuppressive conditions and in intravenous drug users \[[@b8-kjtcv-50-430],[@b9-kjtcv-50-430]\].

A European multicenter collaboration of 16 centers was conducted to retrospectively evaluate the durability of endovascular aortic repair in patients with mycotic aortic aneurysms, by assessing late infection-related complications and long-term survival. In that study, 5% of patients were converted to open repair during a mean follow-up period of 35 months, and the 5-year survival rate was 55% \[[@b10-kjtcv-50-430]\]. In another study, in-hospital mortality was 22.7% in the extra-anatomic reconstruction group and 18.9% in the *in situ* repair group \[[@b11-kjtcv-50-430]\]. Our hospital has considerable experience with *in situ* repair; the in-hospital mortality rate was 10.5% and the 5-year survival rate was 74.9%±11.5% during the 43.2-month follow-up period. *In situ* revascularization has gradually become a standard procedure, based on good results reported in the literature \[[@b11-kjtcv-50-430]--[@b13-kjtcv-50-430]\]. Therefore, the use of stent grafts in the setting of infection could be performed just as a bridge procedure to open repair, because the endograft inevitably becomes infected and fails.

The choice of the ideal conduit is still controversial \[[@b12-kjtcv-50-430]\]. To reduce the risk of reinfection, rifampicin-impregnated grafts or cryopreserved arterial homografts can be used instead of prosthetic grafts. However, no studies have confirmed the superiority of rifampicin-impregnated grafts. Cryopreserved arterial homografts have lower rates of reinfection (approximately 20%) but higher rates of aneurysmal degeneration and rupture (0%--9%) \[[@b7-kjtcv-50-430],[@b14-kjtcv-50-430],[@b15-kjtcv-50-430]\]. Lau et al. \[[@b1-kjtcv-50-430]\] reported that the 5-year survival rate of aortic surgical repair using Dacron prostheses was 71%, with no prosthetic graft infection observed during follow-up. This study also demonstrates that using Dacron prosthetic grafts led to acceptable outcomes in terms of reinfection and surgical outcomes.

To reduce the risk of reinfection, we covered the graft with a pedicle of uninfected tissue, such as the omentum; increased the blood supply; and increased the antibiotic concentration in the area \[[@b11-kjtcv-50-430]\]. In our series, we observed only 1 case of reinfection (5.2%) after *in situ* reconstruction. Our data show that favorable results can be obtained by *in situ* revascularization, aggressive debridement, and soft-tissue coverage in cases without an advanced-stage infection.

Although mycotic aneurysms have been reported in all age groups, the typical patient is elderly and has atherosclerosis \[[@b5-kjtcv-50-430],[@b16-kjtcv-50-430],[@b17-kjtcv-50-430]\]. In our study, the mean age of the patients was 62±7.2 years. Compared with noninfected aortic aneurysms, mycotic aneurysms tend to be symptomatic \[[@b18-kjtcv-50-430]\]. Almost all of our patients had aneurysm-related symptoms, including fever and pain ([Tables 1](#t1-kjtcv-50-430){ref-type="table"}, [2](#t2-kjtcv-50-430){ref-type="table"}). Therefore, early operative intervention is indicated in these cases, especially for older patients with symptomatic aortic aneurysms.

In the literature, the most frequently reported microorganisms related to mycotic aneurysms are *Staphylococcus, Streptococcus,* and Gram-negative microorganisms, such as *Klebsiella pneumoniae* and *Salmonella* \[[@b5-kjtcv-50-430]\]. Gram-negative microorganisms are thought by many to exhibit a more virulent course, because of their ability to invade the normal intima and cause early aneurysm rupture \[[@b3-kjtcv-50-430]\]. In this study, the patient with *Salmonella* presented with a rupture at admission; she also had the longest ICU and hospital stay due to sepsis. Therefore, if a positive culture is found for Gram-negative microorganisms, aggressive surgical treatment and antibiotic suppression therapy are needed to prevent a fatal outcome.

The outcome of surgery depends on several factors, including the type and location of the aneurysm, the form of presentation, the patient's comorbidities, the microorganism that is isolated, the type and duration of antibiotic therapy, and the type of surgery \[[@b11-kjtcv-50-430]\]. Our results suggest that uncontrolled fever, rupture, and Gram-negative microorganisms are risk factors for adverse surgical outcomes.

In our series, because of the lack of power in the sample and the retrospective nature of the study, a robust statistical analysis was not possible. Therefore, a much greater number of cases than were available for this series is necessary to demonstrate any influence of the surgical technique on outcomes.

In conclusion, the early and midterm outcomes of the open repair of mycotic aneurysms were favorable. Aggressive intraoperative debridement with *in situ* prosthetic reconstruction and soft-tissue coverage yielded a high rate of success in these very high-risk patients.
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###### 

Patient characteristics and early outcomes (N=19)

  Characteristic                                Value
  --------------------------------------------- ----------
  Age (yr)                                      62±7.2
  Gender                                        
   Men                                          13 (68)
   Women                                        6 (32)
  Underlying disease                            
   Chronic renal disease                        4 (21)
   Diabetes mellitus                            6 (32)
   Hypertension                                 5 (26)
   Tumors                                       2 (11)
  Symptoms and clinical findings                
   Pain                                         10 (53)
   Fever                                        8 (42)
   Hematochezia, hemoptysis                     4 (21)
   Extremities weakness                         2 (11)
   None                                         1 (5)
  Location of mycotic aneurysm                  
   Ascending aorta                              3 (16)
   Descending thoracic aorta                    6 (32)
   Thoracoabdominal aorta                       2 (11)
   Abdominal aorta                              8 (42)
  In-hospital mortality                         2 (10.5)
   Sepsis                                       1 (5.2)
   Acute myocardial infarction                  1 (5.2)
  Morbidities                                   
   Stroke                                       0
   Postoperative bleeding                       1 (5.2)
   Acute renal failure                          1 (5.2)
   Pulmonary complications                      4 (21.1)
  Length of stay in intensive care unit (day)   11±19.7
  Length of hospital stay (day)                 52±44.6
  Reinfection                                   1 (5.2)

Values are presented as mean±standard deviation or number (%).

###### 

Individual case details

  No.   Age (yr)   Gender   Comorbidity                                                                                     Symptom                                               Preoperative duration (day)   Bacteriology   Location         Conduit              Soft tissue coverage   Outcome      
  ----- ---------- -------- ----------------------------------------------------------------------------------------------- ----------------------------------------------------- ----------------------------- -------------- ---------------- -------------------- ---------------------- ------------ ------------
  1     71         M        ESRD-peritoneal dialysis                                                                        Fever, back pain                                      75                            −              *Enterobacter*   Abdominal            Dacron                 No           Died
  2     77         M                                                                                                        Abdominal pain                                        1                             \+             *S. aureus*      Abdominal            Dacron                 No           Discharged
  3     78         M        Infrarenal aortic aneurysm s/p graft replacement                                                Hematochezia, hematemesis                             1                             None           Abdominal        Gore-Tex             No                     Died         
  4     16         M        Desmoplastic small round cell tumor s/p autologous peripheral blood stem cell transplantation   Fever, cough, hematemesis                             1                             −              *Klebsiella*     Descending           Dacron                 No           Died
  5     57         M        DM, military pulmonary tuberculosis                                                             Chest pain, hemoptysis                                10                            −              *Enterobacter*   Descending           Dacron                 Omental      Died
  6     72         M        DM, ESRD-hemodialysis                                                                           Upper extremity weakness                              0                             None           Abdominal        Dacron               No                     Discharged   
  7     38         F        Left atrial myxoma s/p excision of cardiac mass                                                 Epigastric pain                                       7                             −              *Pseudomonas*    Ascending            Homograft              Pectoralis   Discharged
  8     73         M        HTN, CAOD 3VD, s/p off-pump coronary artery bypass 3 grafts                                     Chest pain                                            7                             \+             *S. aureus*      Thoracoabdominal     Dacron                 No           Died
  9     72         F        Empyema s/p decortication                                                                       Fever                                                 46                            −              Nontyphoidal     Descending           Dacron                 No           Discharged
  10    65         F        DM                                                                                              Fever, abdominal pain, both flank pain                8                             \+             *S. aureus*      Descending           Dacron                 No           Discharged
  11    65         M        HTN, DM, basal cell carcinoma (derma)                                                           Fever, abdominal pain                                 1                                            None             Descending           Dacron                 Omental      Discharged
  12    45         F        SLE, ESRD, CAOD 2VD                                                                                                                                   9                                            None             Abdominal            Dacron                 Omental      Discharged
  13    66         F        HTN, DM, chronic heart failure, ESRD                                                            Abdominal pain                                        7                                            None             Thoracoabdominal     Dacron                 Omental      Discharged
  14    71         M        HTN                                                                                             Fever, weight loss, cough, sputum, chest discomfort   30                            \+             None             Abdominal            Homograft              Omental      Discharged
  15    76         M        HTN, ESRD, CAOD 3VD s/p multiple percutaneous transluminal coronary angioplasty, rule out SLE   Abdominal pain                                        30                            −              None             Abdominal            Homograft              Omental      Discharged
  16    53         M        Ventricular septal defect s/p patch repair                                                      Hemoptysis                                            7                                            *S. aureus*      Ascending            Dacron                 Omental      Discharged
  17    71         M        Infectious spondylitis, endocarditis                                                            Fever, lower extremities weakness                     7                                            *Enterobacter*   Ascending and arch   Dacron                 No           Discharged
  18    65         F        Ruptured abdominal aorta s/p endovascular aneurysm repair                                       Back pain                                             60                                           None             Descending           Dacron                 Omental      Discharged
  19    47         M        Rectal cancer s/p radio therapy                                                                 Fever, chills                                         60                                           None             Abdominal            Dacron                 No           Discharged

ESRD, end-stage renal disease; *S. aureus*, *Staphylococcus aureus*; s/p, status post; DM, diabetes mellitus; HTN, hypertension; CAOD, coronary artery occlusive disease; VD, vessel disease; SLE, systemic lupus erythematosus.
